Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Vascular pathology linked to hand, knee osteoarthritis

29 May 2020
The normalisation of the body’s metabolism was found to help slow down the progression of osteoarthritis – and even promote joint recovery in the long run.

Vascular pathology appears to be associated with the risk of hand and knee osteoarthritis (OA), with a potential causal relationship for knee OA, suggest the results of a systematic review.

Of the 15 studies that met the eligibility criteria, three were of high quality, three were fair, and nine were low. Vascular pathology showed the following features: atherosclerosis, vascular stiffness, and endothelial dysfunction in different vascular beds.

An association was seen between vascular pathology and risk of hand OA in women but not in men, and between vascular pathology and risk of knee OA in both men and women. Two studies, however, did not show an association between vascular pathology and risk of hip OA.

“Based on the limited evidence, it is hard to conclude an association for hip OA,” the investigators said. “Further stronger evidence is needed to determine whether there is a causal relationship.”

Several databases (Scopus, Ovid Medline, and Embase) were searched from inception to February 2019. Medical subject heading terms and keywords were used to identify studies examining the association between vascular pathology and OA. Two reviewers extracted the data and assessed the methodological quality independently. Qualitative evidence synthesis was also carried out.

“Vascular pathology (changes in blood vessels) and OA are both common chronic conditions associated with ageing and obesity, but whether vascular pathology is a risk factor for OA is unclear,” according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 3 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, Yesterday

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.